Financial Report (260508 Evonik FinancialsQ12026)

Financial KPIs Group

P. 2

ESG KPIs

P. 3

Segment KPIs

P. 4-6

Group Income Statement

P. 7-8

Group Balance Sheet

P. 9

Group Cash Flow Statement

P. 10

Group Net Financial Position

P. 11

Definitions

P. 12

in € million

2021 FY

2022 FY

2023 FY

2024 FY

2025 Q1

2025 Q2

2025 Q3

2025 Q4

2025 FY

2026 Q1

External Sales

14,955

18,488

15,267

15,157

3,777

3,499

3,391

3,403

14,069

3,427

Growth (%)

23%

24%

-17%

-1%

-1%

-11%

-12%

-5%

-7%

-9%

Volumes (%)

11%

-4%

-8%

4%

2%

-4%

-6%

2%

-2%

-2%

Prices

12%

18%

-3%

-2%

-2%

-1%

-1%

-2%

-1%

-1%

Exchange Rates

-2%

5%

-2%

-1%

1%

-3%

-3%

-5%

-2%

-5%

Other (incl. M&A)

2%

5%

-4%

-2%

-2%

-3%

-2%

0%

-2%

-1%

Adjusted EBITDA

2,383

2,490

1,656

2,065

560

509

448

357

1,874

475

Margin

15.9%

13.5%

10.8%

13.6%

14.8%

14.5%

13.2%

10.5%

13.3%

13.9%

EBIT

1,173

942

-243

577

299

236

-25

68

578

229

Adjusted EBIT

1,338

1,350

521

1,027

309

250

197

105

861

235

Margin

8.9%

7.3%

3.4%

6.8%

8.2%

7.1%

5.8%

3.1%

6.1%

6.9%

Adjusted EPS

2.12

2.26

0.79

1.67

0.59

0.34

0.27

0.15

1.36

0.34

Free Cash Flow

950

785

801

873

195

-211

300

411

695

183

Cash Conversion Rate1

40%

32%

48%

42%

37%

Capex (Cash outflow for investment in intangible assets, pp&e)

865

865

793

840

190

176

181

201

748

224

Capital employed (annual average)

14,799

16,192

15,406

14,493

14,038

ROCE

9.0%

8.3%

3.4%

7.1%

6.1%

Dividend

1.17 €

1.17 €

1.17 €

1.17 €

1.00 €

Employees (continuing operations)

33,004

34,029

33,409

31,930

31,585

31,273

31,297

31,053

31,053

30,643

1 Free cash flow conversion = FCF / adj. EBITDA

Evonik Group Environment, Social & Governance KPIs

Full set of ESG KPIs published seperately on our IR website: evonik.finance/investor-relations

2021 FY

2022 FY

2023 FY

2024 FY

2025 FY

Strategy & Growth

Sales share with "Next Generation Solutions"

41%

43%

43%

45%

48%

Governance & Compliance

Training rate fighting money laundering

96%

97%

98%

99%

100%

Training rate antitrust law

83%

85%

89%

90%

91%

Training rate fighting corruption

92%

91%

86%

95%

96%

Training rate code of conduct

89%

89%

92%

96%

97%

Training rate Human Rights (new in 2024)

90%

84%

94%

Training rate Data security (new in 2025)

98%

Value Chain & Products

Procurement volume (in € billion)

10.4

13.6

11.3

10.5

9.8

Production output (million metric tons)

9.5

8.4

7.5

7.3

6.0

Use of renewable raw materials in production

9.7%

11.1%

12.0%

9.0%

10.0%

Raw material suppliers covered by TfS assessments

69%

66%

67%

71%

86%

No. of sustainability audits (Evonik/TfS)

284

378

492

596

605

No. of sustainability assessments (Evonik/TfS)

1,345

1,545

1,296

1,309

926

R&D expenses (€ million)

464

461

443

459

418

The environment

Scope 1 greenhouse gas emissions (thousands metric tons CO 2 )

4,381a

4,221a

3890b

3,390

2.99

Scope 2 greenhouse gas emissions (thousands metric tons CO 2 )

1,916a

1,757a

1400b

1,670

1.36

Scope 3 greenhouse gas emissions (million metric tons CO 2 )

23.4

20.5a

18.9b

21.6

19.5

% Reduction in greenhouse gas emissions Scope 1 & 2 (million metric tons CO 2 ) vs base year

-43

-5c

-15c

-20

-31

Total water intake (in million m³)

462d

444d

403

431

427

Specific water intake (in m³ freshwater / metric ton production)

26.8d

29.5d

29.9

32.2

36.7

Production waste (thousand metric tons)

342d

335d

287

306

272

Specific production waste (in ton of waster per metric ton production)

0.036

0.04

0.038

0.042

0.045

Employees

Early employee turnover

2.2%

1.9%

2.2%

1.7%

5.3%

Continuing professional development per employee (hours)

5

4

4

2

2.1

Women at level "Executives" (circle 1)

17.7%

20.3%

22.2%

21.8%

21%

Women at level "Senior management" (circle 2)

17.6%

17.1%

18.5%

19.1%

22%

Women in management (circle 3)

28.7%

29.9%

30.3%

31.4%

32%

Women in management (circles 1-3)

27.9%

29.1%

29.6%

30.7%

32%

Safety

Occupational health performance index

5.6

5.5

5.5

5.5

5.6

Accident frequency rate (no. of accidents / working hours) b

0.19

0.25

0.21

0.14

0.18

Incident frequency rate (no. of accidents / working hours) b

0.48

0.49

0.43

0.44

0.44

a: adjusted figures corresponding to GHG Protocal Standards | b: Correction of data based on methodological improvements | c: for new target period 2021-2030 | d: data corrected for fast-close proces

s

(for ESG KPI definitions please see separate "Definitions" page at the end of the file)

in € million

2021 FY

2022 FY

2023 FY

2024 FY

2025 Q1

2025 Q2

2025 Q3

2025 Q4

2025 FY

2026 Q1

Sales

5,357

6,568

5,608

5,737

1,427

1,367

1,340

1,359

5,492

1,334

Growth (yoy)

19%

23%

-15%

2%

3%

-7%

-9%

-3%

-4%

-7%

Volumes

14%

-3%

-11%

5%

2%

-5%

-8%

0%

-3%

-3%

Prices

5%

13%

1%

-2%

0%

1%

1%

1%

1%

0%

Exchange Rates

-1%

5%

-3%

-1%

1%

-3%

-3%

-5%

-3%

-6%

Other (incl. M&A)

1%

8%

-2%

0%

0%

0%

1%

1%

1%

2%

Sales Additives

3,588

4,523

3,747

3,908

974

942

899

868

3,683

920

Volumes (%)

+

-

-

+

=

-

-

-

-

-

Prices (%)

+

+

=

-

=

=

=

=

=

=

Sales Care

1,768

2,045

1,861

1,829

453

425

441

491

1,809

414

Volumes (%)

+

=

-

=

+

-

-

+

=

-

Prices (%)

+

+

+

=

-

=

+

+

=

=

Adjusted EBITDA

1,086

1,162

852

978

256

254

215

184

909

227

Margin

20.3%

17.7%

15.2%

17.0%

17.9%

18.6%

16.0%

13.5%

16.6%

17.0%

EBITDA yoy Additives

+

+

-

+

+

-

-

=

-

-

EBITDA yoy Care

+

+

-

-

+

-

-

+

+

-

EBIT

558

170

189

120

74

553

152

Adjusted EBIT

663

181

180

140

104

602

152

Capital expenditures

311

50

78

72

100

300

64

Approx. Operating FCF

600

44

112

172

314

642

40

Capital employed (annual average)

6,192

6,054

ROCE

10.7%

9.9%

Employees

9,736

9,746

9,649

9,644

-

9,529

9,805

2019-2023 figures pro-forma (unaudited)

Approx. Operating FCF provided as simplified indication only (unaudited). Calculated as adj. EBITDA, plus/minus NWC change, minus capex. Not including taxes, provisions and other items, thus not adding up to Group FCF.

For sales (volume and price) and EBITDA trends yoy ("+" or "-" in case of >2% deviation; otherwise "=")

in € million

2021 FY

2022 FY

2023 FY

2024 FY

2025 Q1

2025 Q2

2025 Q3

2025 Q4

2025 FY

2026 Q1

Sales

5,827

7,092

5,983

6,089

1,601

1,511

1,445

1,415

5,973

1,450

Growth (yoy)

17%

22%

-16%

2%

6%

-1%

-6%

-6%

-2%

-9%

Volumes

11%

-3%

-8%

2%

6%

1%

-2%

2%

2%

-1%

Prices

8%

20%

-4%

0%

-3%

-1%

-1%

-3%

-2%

-1%

Exchange Rates

-2%

5%

-4%

-1%

1%

-4%

-3%

-5%

-3%

-6%

Other (incl. M&A)

0%

0%

0%

1%

2%

3%

0%

0%

1%

-1%

Sales Organics

1,681

1,868

1,742

1,664

426

401

411

395

1,634

390

Volumes (%)

+

-

-

+

+

-

+

+

+

=

Prices (%)

+

+

=

-

-

=

-

-

-

-

Sales Inorganics

2,357

3,031

2,491

2,490

621

614

595

566

2,395

577

Volumes (%)

+

=

-

+

=

-

-

=

=

-

Prices (%)

+

+

=

-

=

=

=

-

=

=

Sales Animal Nutrition

1,789

2,193

1,750

1,935

554

496

439

454

1,944

484

Volumes (%)

+

-

=

=

+

+

-

=

+

+

Prices (%)

+

+

-

+

-

-

-

-

-

-

Adjusted EBITDA

1,233

1,207

752

1,023

291

266

202

186

944

241

Margin

21.2%

17.0%

12.6%

16.8%

18.2%

17.6%

14.0%

13.1%

15.8%

16.6%

EBITDA yoy Organics

+

=

-

-

+

-

-

-

-

+

EBITDA yoy Inorganics

+

+

-

+

-

=

-

+

-

+

EBITDA yoy Animal Nutrition

+

-

-

+

+

+

-

-

-

-

EBIT

517

183

137

65

60

445

125

Adjusted EBIT

565

181

150

89

71

492

129

Capital expenditures

367

56

82

72

132

342

60

Approx. Operating FCF

513

156

85

182

250

673

135

Capital employed (annual average)

7,018

6,907

ROCE

8.1%

7.1%

Employees

9,568

9,405

9,312

9,189

-

9,177

9,458

2019-2023 figures pro-forma (unaudited)

Approx. Operating FCF provided as simplified indication only (unaudited). Calculated as adj. EBITDA, plus/minus NWC change, minus capex. Not including taxes, provisions and other items, thus not adding up to Group FCF.

For sales (volume and price) and EBITDA trends yoy ("+" or "-" in case of >2% deviation; otherwise "=")

in € million

2021 FY

2022 FY

2023 FY

2024 FY

2025 Q1

2025 Q2

2025 Q3

2025 Q4

2025 FY

2026 Q1

Sales Infrastructure & Other

3,771

4,827

3,675

3,331

749

621

606

629

2,604

643

Sales Infrastructure

3,146

708

584

574

583

2,449

577

Sales Other

185

41

37

32

46

155

66

Adjusted EBITDA Infrastructure & Other

96

124

54

64

13

-11

31

-13

21

7

Adj. EBITDA Infrastructure

275

61

38

54

59

213

47

Adj. EBITDA Other

-211

-48

-49

-23

-72

-192

-40

EBIT

-316

-641

-611

-498

-54

-90

-210

-66

-420

-48

Adjusted EBIT

-228

-224

-296

-201

-53

-80

-32

-67

-233

-46

Capital expenditures

292

241

189

138

27

25

29

50

130

21

Employees

16,116

16,504

16,184

12,626

12,434

12,347

11,380

1 Infrastructure is comprised of two distinct businesses 1) SYNEQT = infrastructure assets in Marl and Wesseling and 2) Oxeno = C4 value chain in Marl and Antwerp

in € million

2021 FY

2022 FY

2023 FY

2024 FY

2025 Q1

2025 Q2

2025 Q3

2025 Q4

2025 FY

2026 Q1

Sales

14,955

18,488

15,267

15,157

3,777

3,499

3,391

3,403

14,069

3,427

Cost of sales

-10,925

-14,257

-12,567

-11,419

-2,769

-2,568

-2,775

-2,714

-10,825

-2,563

Gross profit on sales

4,030

4,231

2,700

3,738

1,008

931

616

689

3,244

864

Selling expenses

-1,717

-2,035

-1,836

-1,894

-454

-434

-420

-428

-1,736

-419

Research and development expenses

-464

-460

-443

-459

-106

-105

-104

-102

-418

-94

General administrative expenses

-546

-554

-488

-740

-126

-125

-111

-113

-474

-114

Other operating income & expenses

-138

-252

-186

-89

-25

-33

-7

13

-52

-9

Result from investments recognized at equity

8

12

10

21

2

2

1

9

14

1

Income before financial result and income taxes, cont. ops. = EBIT

1,173

942

-243

577

299

236

-25

68

578

229

Financial Result

-88

-19

-108

-143

-29

-44

-52

-30

-156

-46

Income before income taxes, continuing operations

1,085

923

-351

434

270

192

-77

38

422

183

Income taxes

-316

-369

-101

-194

-34

-68

-25

-18

-145

-54

Income after taxes, continuing operations

769

554

-452

240

236

124

-102

20

277

129

Income after taxes, discontinued operations

-2

1

-

0

0

0

0

0

0

0

Income after taxes

767

555

-452

240

236

124

-102

20

277

129

thereof attributable to non-controlling interests

21

15

13

18

3

4

4

2

12

4

Shareholders of EVONIK Industries AG (net income)

746

540

-465

222

233

120

-106

18

265

125

EPS

1.60

1.16

-1.00

0.48

0.50

0.26

-0.23

0.04

0.57

0.27

in € million

2021 FY

2022 FY

2023 FY

2024 FY

2025 Q1

2025 Q2

2025 Q3

2025 Q4

2025 FY

2026 Q1

Sales

14,955

18,488

15,267

15,157

3,777

3,499

3,391

3,403

14,069

3,427

Adjusted EBITDA

2,383

2,490

1,656

2,065

560

509

448

357

1,874

475

Adjusted depreciation and amortization

-1,045

-1,140

-1,135

-1,038

-251

-259

-251

-252

-1,013

-240

Adjusted EBIT

1,338

1,350

521

1,027

309

250

197

105

861

235

Adjusted net financial result

-97

-19

-103

-143

-29

-44

-52

-37

-162

-46

Adjusted D&A on intangible assets

162

169

153

144

34

32

33

32

131

32

Adjusted income before income taxes

1,403

1,500

571

1,028

314

238

178

100

830

221

Adjusted income taxes, continuing operations

-396

-431

-188

-233

-36

-74

-46

-28

-184

-59

Adjusted income after taxes

1,007

1,069

383

795

278

164

132

72

646

162

Adjusted non-controlling interest

-21

-15

-13

-18

-3

-4

-4

-1

-12

-4

Adjusted net income

986

1,054

370

777

275

160

128

71

634

158

Adjusted EPS

2.12

2.26

0.79

1.67

0.59

0.34

0.27

0.15

1.36

0.34

Adjustments

in € million

2021 FY

2022 FY

2023 FY

2024 FY

2025 Q1

2025 Q2

2025 Q3

2025 Q4

2025 FY

2026 Q1

Restructuring measures

-32

-121

-64

-405

-12

7

-31

-6

-42

-4

Acquisitions and divestments

-29

40

-237

-34

-11

4

0

-7

-14

0

Other special items

-104

-327

-463

-11

13

-25

-191

-24

-227

-2

= Adjustments

-165

-408

-764

-450

-10

-14

-222

-37

-283

-6

Adjustment categories changed as of December 31, 2023 to avoid overlaps between categories; prior year figures restated

in € million

2021 FY

2022 FY

2023 FY

2024 FY

2025 Q1

2025 Q2

2025 Q3

2025 FY

2026 Q1

Intangible assets

6,045

5,710

5,525

5,571

5,426

5,176

5,131

5,097

5,122

Property, plant and equipment

6,963

6,962

6,294

6,450

6,305

6,127

5,933

6,006

6,051

Right of use assets (capitalized leasing)

608

972

965

947

905

867

893

892

867

Investments recognized at equity

81

88

52

49

51

45

45

45

46

Trade accounts receivable

67

54

1

1

Financial assets

581

441

460

467

424

455

418

419

397

Deferred tax assets

1,755

890

642

664

629

624

659

436

430

Other income tax assets

16

19

20

25

24

22

22

22

22

Other non-financial assets

125

64

78

69

110

71

87

96

90

Non-current assets

16,174

15,146

14,036

14,242

13,874

13,454

13,242

13,014

13,026

Inventories

2,548

2,820

2,349

2,662

2,751

2,649

2,555

2,300

2,429

Other income tax assets

199

98

209

166

138

103

86

94

95

Trade accounts receivable

1,954

1,898

1,607

1,622

1,732

1,625

1,581

1,525

1,728

Other non-financial assets

382

517

373

381

440

377

363

333

378

Financial assets

571

610

381

216

574

467

266

220

212

Cash and cash equivalents

456

645

749

461

733

379

454

495

589

Current assets

6,110

6,588

5,668

5,508

6,368

5,600

5,305

4,967

5,431

Assets held for sale

0

76

236

0

0

0

0

0

0

Current assets

6,110

6,664

5,904

5,508

6,368

5,600

5,305

4,967

5,431

Total assets

22,284

21,810

19,940

19,750

20,242

19,054

18,547

17,981

18,457

in € million

2021 FY

2022 FY

2023 FY

2024 FY

2025 Q1

2025 Q2

2025 Q3

2025 FY

2026 Q1

Issued capital

466

466

466

466

466

466

466

466

466

Reserves

8,823

10,508

8,444

8,554

8,719

8,028

7,883

7,644

7,764

Equity attributable to shareholders of Evonik Industries AG

9,289

10,974

8,910

9,020

9,185

8,494

8,349

8,110

8,230

Equity attributable to non-controlling interests

83

82

76

80

82

65

64

64

68

Total equity

9,372

11,056

8,986

9,100

9,267

8,559

8,413

8,174

8,298

Provisions for pensions and other post-employment benefits

3,766

1,359

1,858

1,662

1,449

1,383

1,387

1,490

1,547

Other provisions

657

542

517

734

734

651

667

591

597

Deferred tax liabilities

628

661

608

638

633

625

629

576

592

Other income tax liabilities

195

246

268

254

258

268

246

228

231

Financial liabilities

3,531

4,117

3,502

3,162

3,629

3,586

3,663

3,476

3,471

Other payables

143

182

153

141

97

109

95

118

122

Non-current liabilities

8,920

7,107

6,906

6,591

6,800

6,622

6,687

6,479

6,560

Other provisions

892

732

606

923

955

695

724

787

818

Other income tax liabilities

211

189

124

87

86

63

59

58

79

Financial liabilities

477

429

1,153

1,034

941

1,215

830

689

684

Trade accounts payable

2,022

1,735

1,521

1,600

1,702

1,440

1,359

1,401

1,521

Other payables

390

501

457

415

491

460

475

393

497

Current liabilities

3,992

3,586

3,861

4,059

4,175

3,873

3,447

3,328

3,599

Liabilities associated with assets held for sale

0

61

187

0

0

0

0

0

0

Current liabilities

3,992

3,647

4,048

4,059

4,175

3,873

3,447

3,328

3,599

Total equity and liabilities

22,284

21,810

19,940

19,750

20,242

19,054

18,547

17,981

18,457

in € million

2021 FY

2022 FY

2023 FY

2024 FY

2025 Q1

2025 Q2

2025 Q3

2025 Q4

2025 FY

2026 Q1

Income before financial result and income taxes, continuing operations = EBIT

1,173

942

-243

577

299

236

-25

68

578

229

Depreciation, amortization, impairment losses/reversal of impairment losses on non-current a

1,073

1,568

1,841

1,117

240

260

428

275

1,203

239

Result from investments recognized at equity

-8

-12

-10

-21

-2

-3

0

-9

-14

-1

Gains/losses on disposal of non current assets

43

-50

-1

22

15

4

5

-13

11

-2

Change in inventories

-675

-270

310

-297

-140

7

94

259

220

-104

Change in trade accounts receivable

-449

42

105

21

-143

-16

52

112

5

-183

Change in trade accounts payable and current advance payments received from customers

680

-257

-157

74

185

-228

-67

-32

-142

187

Change in provisions for pensions and other post-employment benefits

83

-19

-55

-48

-4

-13

-28

-4

-49

-8

Change in other provisions

207

-149

-141

535

37

-341

40

10

-254

27

Change in miscellaneous assets/liabilities

-23

10

152

-81

-100

78

7

-6

-21

46

Cash inflows from dividends

19

19

25

27

0

19

0

7

26

0

Tax payments relating to carve-out of the methacrylates business

-

-

-

-

-

-

-

-

-

-

Cash inflows/outflows for income taxes

-308

-174

-232

-213

-2

-38

-25

-55

-120

-23

Cash flow from operating activities, continuing operations

1,815

1,650

1,594

1,713

385

-35

481

612

1,443

407

Cash flow from operating activities, discontinued operations

0

0

0

0

0

0

0

0

0

0

Cash flow from operating activities

1,815

1,650

1,594

1,713

385

-35

481

612

1,443

407

Cash outflows for investments in intangible assets, property, plant and equipment, investment

-865

-865

-793

-840

-190

-176

-181

-201

-748

-224

Cash outflows for investments in shareholdings

-85

-27

-76

-15

0

0

-1

0

0

0

Cash outflows for loss from divestments of shareholdings

-145

97

-32

-13

0

-1

0

0

-2

0

Cash outflows from divestments of businesses and other shareholdings

-21

-

-5

-6

0

0

0

0

0

0

Cash inflows from divestments of intangible assets, property, plant and equipment, investmen

9

5

15

21

8

0

1

12

21

10

Cash inflows for loss from divestments of shareholdings

2

-

43

16

3

6

0

9

18

0

Cash inflows for investments in shareholdings

2

0

2

1

0

10

13

4

Cash inflows/outflows relating to securities, deposits and loans

23

-3

161

137

-352

199

164

-4

8

3

Cash inflows from interest

12

16

32

37

18

7

6

5

38

4

Cash flow from investing activities, continuing operations

-1,070

-777

-653

-663

-511

36

-11

-169

-652

-203

Cash flow from investing activities, discontinued operations

0

0

0

0

0

0

0

0

0

0

Cash flow from investing activities

-1,070

-777

-653

-663

-511

36

-11

-169

-652

-203

Cash inflows/outflows relating to capital contributions

0

0

0

0

1

3

0

0

4

0

Cash outflows for dividends to shareholders of Evonik Industries AG

-536

-545

-545

-545

-

-545

0

0

-545

0

Cash outflows for dividends to non-controlling interests

-21

-13

-10

-20

-1

-4

-4

-1

-10

-2

Cash infows/outflows from changes in ownership interests in subsidiaries without loss of cont

0

-5

-

0

0

-19

0

0

-19

0

Cash outflows for the purchase of treasury shares

-15

-16

-16

-12

0

-1

0

0

-1

0

Cash inflows from the sale of treasury shares

12

12

12

9

0

1

0

0

1

0

Cash inflows from the addition of financial liabilities

655

1,649

716

708

521

308

921

97

1,833

71

Cash outflows for repayment of financial liabilities

-948

-1,577

-893

-1,354

-107

-79

-1,252

-485

-1,909

-172

Cash inflows/outflows in connection with financial transactions

91

-104

12

-7

2

5

0

11

16

20

Cash outflows for interest

-94

-73

-99

-109

-14

-12

-53

-22

-101

-29

Cash flow from financing activities, continuing operations

-856

-672

-823

-1,330

402

-343

-388

-400

-731

-112

Cash flow from financing activities, discontinued operations

0

0

0

0

0

0

0

0

0

0

Cash flow from financing activities

-856

-672

-823

-1,330

402

-343

-388

-400

-731

-112

Change in cash and cash equivalents

-111

201

118

-280

276

-342

82

43

60

92

Cash and cash equivalents as of beginning of period

563

456

645

749

461

735

379

454

461

495

Change in cash and cash equivalents

-111

201

118

-280

276

-342

82

43

60

92

Changes in exchange rates and other changes in cash and cash equivalents

4

-12

-14

-8

-3

-14

-7

-2

-26

2

Cash and cash equivalents as of end of period

456

645

749

461

734

379

454

495

495

589

Cash and cash equivalents included in assets held for sale

0

0

0

0

0

0

0

0

0

0

Cash and cash equivalents as on the balance sheet as of end of period

456

645

749

461

734

379

454

495

495

589

in € million

2021 FY

2022 FY

2023 FY

2024 FY

2025 Q1

2025 Q2

2025 Q3

2025 FY

2026 Q1

Non-current financial liabilities

-3,527

-4,074

-3,320

-2,961

-3,429

-3,393

-3,482

-3,314

-3,285

Current financial liabilitites

-232

-243

-1,006

-883

-845

-1,136

-771

-617

-562

Financial debt

-3,759

-4,317

-4,326

-3,844

-4,274

-4,529

-4,253

-3,931

-3,847

- Cash and cash equivalents

456

645

749

461

733

379

454

495

589

- Current securities

446

413

261

128

482

285

121

124

117

- Other financial assets

0

2

6

2

1

1

1

1

1

Financial assets

902

1,060

1,016

591

1,216

665

576

620

707

Net financial debt/cash as stated on the balance sheet

-2,857

-3,257

-3,310

-3,253

-3,058

-3,864

-3,677

-3,311

-3,140

Net financial debt/cash, discontinued operations

-

-

-

0

0

0

0

0

0

Net financial debt/cash including discontinued operations

-2,857

-3,257

-3,310

-3,253

-3,058

-3,864

-3,677

-3,311

-3,140

Financial KPI Definitions

Adjusted EBIT

Earnings before financial result and taxes, after adjustments. Earnings indicator showing Evonik's operating earnings performance irrespective of the structure of its assets.

Adjusted EBITDA

Earnings before financial result, taxes, depreciation and amortization, after adjustments. Earnings indicator showing Evonik's operating earnings performance irrespective of the structure of its assets and its investment profile. This is a

cash flow-related indicator which is used in particular in the adjusted EBITDA margin to show the relationship to sales as a basis for comparison with competitors.

Adjusted net income

We use adjusted net income to assess the earnings power of the continuing operations, especially on a long-term view, and to forecast future development. The calculation starts from EBITDA after adjustment for special items. The financial result is then adjusted for income and expenses in connection with the acquisition/divestment of shareholdings and other income and expense items that, by nature or amount, do not form part of typical current financing activities. Further, we deduct amortization of intangible assets, as they mainly result from acquisitions, and adjust income tax for taxes on special items.

Adjustments

Evonik refers to the special items that are factored out when calculating the operational performance indicators adjusted EBITDA and adjusted EBIT as adjustments. They include restructuring, impairment losses/reversals of impairment losses, income and expenses in connection with the purchase/disposal of investments in companies, and other income and expense items that, due to their nature or amount, do not reflect the typical operating business.

Free Cash Flow

The free cash flow is a measure of the company's internal financing capacity. It shows the cash that is available to pay dividends, make acquisitions and repay borrowing. The free cash flow is calculated from the cash flow from operating

activities, continuing operations, less outflows for capital expenditures on intangible assets, property, plant and equipment.

ROCE

The return on capital employed is a measure of the profitability of capital employed. It is calculated by dividing adjusted EBIT by the average capital employed in the reporting period.

ESG KPI Definitions

Value added in € million

We use an impact valuation to regularly measure and analyze the direct and indirect impacts from an economic, ecological, and social perspective. This supplements our established analytical approaches. We anticipate that this will allow early identification of potential future opportunities and risks, make our business model more resilient, and improve understanding of the long-term value that our business activities create for society. We aim to assign a monetary value to individual indicators such as continuing development of employees, employment impacts, and global warming so they can be compared. Most of the factors used for this are publicly available.

Sales share with "Next Generation Solutions"

Sales share of products with superior sustainability benefits to customers ("Next Generation Solutions"); derived from sustainability analysis of our businesses based on the principles and content of the WBCSD Portfolio Sustainability Assessments (PSA)

For more information please see Evonik website:

Responsibility - Value Chain & Products - Sustainability Analysis

Internal Investigations

Internal investigations are initiated when there is a suspected violation of compliance rules (including the code of conduct, antitrust law and the rules on fighting and preventing corruption). Since 2018, the scope of reporting has covered all internal investigations in the Evonik Group. Before that, only the areas covered by the House of Compliance were included.

Disciplinary Measures

Disciplinary measures are taken as a result of an internal investigation. A disciplinary measure can result in an employee's dismissal, warning or reprimand, transfer to a different position or further awareness enhancement. In rare cases, legal proceedings (civil or criminal) had to be initiated.

Raw Material Suppliers Covered by TfS Assessments

This number indicates how many raw material suppliers have been covered by TfS assessments in that year. The chemical industry set up the Together for Sustainability (TfS) initiative in 2011 with the goal to harmonize global standards in the supply chain to create transparency and make it easier for both suppliers and customers to reliably assess and evaluate sustainability performance. This includes assessing the suppliers' quality, grade of environmental protection, safety, health, energy management, the assessment of potential risk factors. Evonik is one of the founding members of this initiative.

Greenhouse Gas Emissions

Scope 1: Evonik's direct energy and process-related emissions;

Scope 2: Purchased energy (net, total purchased power and steam - sale of power and steam to third parties; market-based approach);

Scope 3: Indirect emissions, including emissions from the production of purchased raw materials, packaging materials, capital goods, energy-related emissions outside scopes 1 and 2, emissions from inbound shipments of raw materials, from the disposal of production waste, business trips, commuting by employees, Evonik's fleet of vehicles, enregy requierements for offices and emissions from the disposal and recycling of products sold.

Early Employee Turnover

Turnover of newly hired employees within the first year of employment

Management circles/ levels

Management circle 1 = executive functions, i.e., top management functions in the Evonik Group

Management circle 2 = senior management functions, i.e., key functions in the divisions, regions, service units, and corporate functions Management circle 3 = further management functions

Occupational Health Performance Index

This index shows the extent to which internal requirements have been implemented and goals achieved. It is calculated from two parameters from each of the following areas: occupational medicine, health promotion and emergency medical management. Both the quality and the scope of the measures are taken into account. The index is calculated annually.

Specific water intake in m3 freshwater per metric ton production

Freshwater usage in relation to production.

Total water intake

Evonik's consumption of freshwater is the total of drinking water, groundwater, surface water, and recycled water. Total water intake is the sum of total freshwater and salt water (sea water).